| 方向明 易高 王志敏 沈璐 潘嘉宇.乌司他丁联合阿托莫兰对感染性休克患者血清IL-6, TNF-alpha和PCT 水平
的影响[J].,2017,17(3):496-499 |
| 乌司他丁联合阿托莫兰对感染性休克患者血清IL-6, TNF-alpha和PCT 水平
的影响 |
| Effects of Ulinastatin Combined with Atuomolan on the Levels of IL-6,TNF-alpha and PCT in Patients with Septic Shock |
| |
| DOI： |
| 中文关键词: 乌司他丁 阿托莫兰 感染性休克 IL-6 TNF-alpha PCT |
| 英文关键词: Ulinastatin Atuomolan Septic shock IL-6 TNF-alpha PCT |
| 基金项目:广州市医药卫生科技项目（20151A011095） |
|
| 摘要点击次数: 819 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探究乌司他丁联合阿托莫兰对感染性休克患者血清白细胞介素-6(IL-6)、肿瘤坏死因子-alpha(TNF-alpha)和降钙素原（PCT）
水平的影响。方法：选择2013 年6 月～2015年12 月期间我院收治感染性休克患者79 例为研究对象；采用随机数字法将其分为
观察组（39 例）和对照组（40 例），观察组患者给予乌司他丁联合阿托莫兰治疗，对照组给予常规抗感染治疗；观察并比较两组患
者治疗前后IL-6、TNF-alpha和PCT 水平，比较两组患者药物不良反应、多器官功能障碍综合征(MODS)发生率及病死率。结果：治疗
前两组患者间IL-6、TNF-alpha及PCT 水平均无差异（P<0.05）；治疗后两组患者IL-6、TNF-alpha及PCT 均显著下降，且观察组IL-6、
TNF-alpha及PCT 水平低于对照组（P<0.05）；治疗过程中两组患者药物不良反应发生率无差异（P>0.05）；治疗后观察组MODS 及死
亡发生率均低于对照组（P<0.05）。结论：乌司他丁联合阿托莫兰能够改善对感染性休克患者炎症反应，降低机体IL-6、TNF-alpha及
PCT 水平，降低MODS 发生率及病死率，在临床治疗感染性休克具有重要价值。 |
| 英文摘要: |
| Objective:To explore the effects of ulinastatin combined with atuomolan on the levels of IL-6, TNF-alpha and PCT in patients
with septic shock.Methods:79 cases of septic shock in our hospital were selected as the research objects from June 2013 to December
2015,which were divided into observation group (39 cases) and control group (40 cases) by random number method; The patients
in the observation group were given ulinastatin combined with reduced glutathione treatment, the patients in control group were only given
conventional anti-infection treatment; To observe and compare the levels of IL-6, TNF-alpha and PCT before and after treatment in both
groups;To compare the incidence of adverse drug reactions, multiple organ dysfunction syndrome (MODS) and mortality between two
groups after treatment.Results:There were no differences in the levels of IL-6, TNF-alpha and PCT between two groups before treatment
(P<0.05); The levels of IL-6, TNF-alpha and PCT were significantly decreased after treatment; and the levels of IL-6, TNF-alpha and PCT in observation
group were lower than that of control group (P<0.05); There was no difference in the incidence of adverse drug reactions between
two groups in the course of treatment (P>0.05); The incidence of MODS and mortality in the observation group were lower than
those in the control group after treatment (P<0.05).Conclusion:Ulinastatin combined with atuomolan can improve the inflammatory response
in patients with septic shock; To reduce the levels of IL-6, TNF-alpha and PCT, and to reduce the incidence and mortality of MODS,
which has great value in clinical treatment of septic shock. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
